End-of-day quote
Taiwan S.E.
06:00:00 2024-07-11 pm EDT
5-day change
1st Jan Change
68.8
TWD
-2.41%
+1.78%
+5.68%
Tanvex BioPharma, Inc.(TWSE:6541) added to Taiwan TAIEX Index
Tanvex BioPharma, Inc Added to Taiwan TAIEX Index.
Tanvex BioPharma, Inc. Announces CFO Changes, Effective June 30, 2024
Jun. 28
CI
Tanvex BioPharma, Inc. Appoints Val Chen as Corporate Governance Officer, Effective July 1, 2024
Jun. 19
CI
Tanvex BioPharma, Inc. Announces Change of Audit Committee Members
Jun. 19
CI
Tanvex BioPharma, Inc. Announces Change of Remuneration Committee Members
Jun. 19
CI
Tanvex BioPharma, Inc. Announces Board Changes
Jun. 19
CI
Tanvex BioPharma, Inc.(TWSE:6541) dropped from Taiwan TAIEX Index
Jun. 13
CI
Tanvex BioPharma, Inc.(TWSE:6541) dropped from S&P Global BMI Index
May. 27
CI
Tanvex BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 12
CI
Tanvex BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 14
CI
Tanvex BioPharma, Inc. Announces the Appointment of James Williamson as Accounting Officer
Feb. 06
CI
Tanvex BioPharma, Inc. Announces the Appointment of Chen, Lin-Cheng as CEO
Feb. 06
CI
Tanvex Biologics Corporation announced that it expects to receive $5 million in funding from Tanvex BioPharma, Inc.
Feb. 05
CI
Tanvex BioPharma USA, Inc. announced that it expects to receive $50 million in funding from Tanvex BioPharma, Inc.
Feb. 05
CI
Tanvex BioPharma, Inc. Announces the Resignation of Ken Huang as Accounting Officer
Jan. 05
CI
Tanvex BioPharma, Inc. Announces Change of Chairman
Dec. 29
CI
Tanvex BioPharma, Inc. Announces Resignation of Yun Yen Chairperson and Director, Effective December 29, 2023
Dec. 21
CI
Tanvex BioPharma, Inc. Announces Change of Corporate Governance Officer
Dec. 21
CI
Tanvex BioPharma, Inc. Announces Resignation of Yun Yen as CEO, Effective December 29, 2023
Dec. 21
CI
Tanvex BioPharma, Inc. Announces Resignation of Yun Yen as Chairman/President, Effective December 29, 2023
Dec. 21
CI
Tanvex BioPharma, Inc. Announces the Resignation of Stacey Tsai as Acting Spokesperson and Corporate Governance Officer
Nov. 30
CI
Tanvex BioPharma, Inc. Appoints Wen Chung Yeh as Chief Financial Officer
Nov. 13
CI
Tanvex BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 12
CI
Tanvex BioPharma, Inc. Announces Management Changes
Nov. 01
CI
Tanvex BioPharma, Inc.(TWSE:6541) added to S&P Global BMI Index
23-09-17
CI
Tanvex BioPharma, Inc.(TWSE:6541) added to Taiwan TAIEX Index
23-09-06
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Tanvex BioPharma, Inc. is a Cayman Islands-based biopharmaceutical company focused on the biosimilar market. The company has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Companyâs product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The Company offers a vertically integrated manufacturing platform for biopharmaceuticals. The Company is developing and delivering biologic and biosimilar drugs to people.
More about the company
1st Jan change
Capi.
+5.68% 347M +20.12% 126B +25.25% 119B +25.56% 27.95B -19.51% 20.5B -14.36% 17.12B -15.63% 16.1B -46.67% 14.97B +11.89% 14.84B +57.74% 14.38B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1